Spironolactone vs Eplerenone for Primary Aldosteronism?
At a Glance
Spironolactone is usually first-line for primary aldosteronism because it is effective and affordable, but eplerenone causes fewer hormone-related side effects. Both medicines can raise potassium or affect kidney function, so blood-test monitoring is needed, and their doses are not interchangeable.
In this answer
4 sections
Both spironolactone and eplerenone treat primary aldosteronism by blocking the effects of excess aldosterone in your body [1]. When primary aldosteronism affects both adrenal glands (bilateral disease), or when surgery is not an option for unilateral disease, medical therapy with one of these drugs is often the standard of care.
Spironolactone is generally the first-line medical therapy when a medication in this class is indicated. It is highly effective, widely available, and usually less expensive [1]. However, it can cause side effects related to sex hormones, such as breast tenderness or menstrual irregularities. Eplerenone is a more selective alternative that is much less likely to cause these side effects [2]. Eplerenone can be more expensive and may require twice-daily dosing [1].
Warning: Spironolactone and eplerenone are not milligram-for-milligram interchangeable. Never start, stop, or adjust your dose without your clinician’s guidance.
How They Work
Both medications belong to a class of drugs called mineralocorticoid receptor antagonists (MRAs). They work by preventing aldosterone from binding to its receptors. This helps lower your blood pressure and reduces your body’s excretion of potassium, bringing low potassium levels back toward normal [3][4].
When dosed appropriately, both medications are effective [1]. Spironolactone is generally more potent. Some research suggests it may be slightly better at lowering blood pressure and correcting low potassium, though differences are small [2][5]. Because eplerenone is less potent, you may need a higher dose or a twice-daily schedule to achieve the same results [6].
Monitoring Renin
Your doctor will likely monitor a blood test called renin to see if the medication is working. Excess aldosterone suppresses renin, so a rise in your renin levels is a useful biomarker that the medication is adequately blocking the excess aldosterone [1][7]. There is no single universal “target” number; your doctor will interpret your renin based on the specific lab assay used, alongside your blood pressure, potassium, and overall clinical picture.
Side Effect Differences
A key difference between the two medications is their side effect profile, specifically regarding sex hormones.
Spironolactone Side Effects
Spironolactone effectively blocks the aldosterone receptor, but it also binds to androgen receptors (which respond to hormones like testosterone) and stimulates progesterone receptors [3][1]. This can lead to anti-androgen side effects:
- Breast tenderness or gynecomastia (breast enlargement) in men [2]
- Menstrual irregularities in women [8]
- Reduced libido or sexual dysfunction [8]
These side effects can occur at any dose, though the risk generally increases at higher doses and with longer-term use [9].
Eplerenone Side Effects
Eplerenone was designed to be more selective, meaning it primarily targets the aldosterone receptor without interfering as much with sex hormones [3][10]. As a result, it is much less likely to cause gynecomastia or menstrual changes, though sexual symptoms are still possible [11][2]. It is often prescribed as an alternative if a patient experiences bothersome side effects from spironolactone [12].
Shared Risks: Potassium, Kidneys, and Drug Interactions
Because both medications work the same way, they share important risks.
High Potassium (Hyperkalemia)
While these drugs correct low potassium, they can also cause your body to hold onto too much potassium, raising it to dangerously high levels [13]. This risk is higher if you have kidney disease or are older [14]. High potassium often causes no symptoms, but severe cases can lead to severe weakness, palpitations, or fainting—seek urgent medical help if these occur.
You must review all your medications and supplements with your doctor before starting or changing your dose. The risk of high potassium increases significantly if you take:
- Potassium supplements or potassium-containing salt substitutes (these are often stopped once MRA treatment begins) [4]
- Blood pressure medications like ACE inhibitors or ARBs [14]
- NSAID pain relievers (like ibuprofen)
- Certain antibiotics (like trimethoprim)
Eplerenone also has important interactions with drugs that affect the CYP3A4 liver enzyme, which can change how it is processed in the body. Check with your pharmacist before starting any new prescription or over-the-counter medicine.
Kidney Function Changes
Your kidney function is measured by a blood test called eGFR (estimated glomerular filtration rate). When you start treatment, your eGFR may decline [15]. Excess aldosterone forces the kidneys to filter too quickly (a process called hyperfiltration). MRAs lower the pressure inside the kidneys, returning filtration to a more normal rate, which causes the eGFR number to drop [16][17].
While a modest drop can be an expected hemodynamic change rather than actual kidney damage [18], any significant, rapid, or progressive change requires prompt clinical review to ensure your blood pressure hasn’t dropped too low or that there is no underlying kidney injury [19].
Monitoring Plan
Your doctor should order baseline blood tests to check your potassium and eGFR before you start. These should be rechecked shortly after starting the medication and after any dose change, with ongoing follow-up based on your individual risk factors [14]. Other common side effects to watch for include dizziness, low blood pressure, and increased urination.
Comparison Summary
| Feature | Spironolactone | Eplerenone |
|---|---|---|
| Receptor Selectivity | Less selective (affects sex hormone receptors) | More selective for the aldosterone receptor |
| Hormone Side Effects | Higher risk (gynecomastia, menstrual changes) | Much lower risk |
| Typical Dosing Frequency | Often once daily | Often twice daily |
| Potassium & Kidney Risks | Requires strict lab monitoring | Requires strict lab monitoring |
| Cost & Availability | Usually less expensive, widely available generic | Can be more expensive, generic available but varies |
Common questions in this guide
What is the main difference between spironolactone and eplerenone for primary aldosteronism?
Which drug is usually started first for primary aldosteronism?
When might medication be used instead of surgery for primary aldosteronism?
Can I switch between spironolactone and eplerenone at the same dose?
What monitoring is needed after starting either medicine?
Why is renin checked during treatment for primary aldosteronism?
What side effects and drug interactions should I watch for?
Related questions
Show more
Get notified when new evidence is published on hyperaldosteronism.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.
Adler GK, Stowasser M, Correa RR, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(9)):2453-2495 doi:10.1210/clinem/dgaf284.
PMID: 40658480 - 2
Comparison of different medical treatments for primary hyperaldosteronism: a systematic review and network meta-analysis.
Ho WY, Hsiao CC, Wu PH, et al.
Therapeutic advances in chronic disease 2024; (15()):20406223241239775 doi:10.1177/20406223241239775.
PMID: 38511069 - 3
Pharmacological treatment of aldosterone excess.
Deinum J, Riksen NP, Lenders JW
Pharmacology & therapeutics 2015; (154()):120-33.
PMID: 26213109 - 4
Diagnosis and treatment of primary aldosteronism: practical clinical perspectives.
Young WF
Journal of internal medicine 2019; (285(2)):126-148 doi:10.1111/joim.12831.
PMID: 30255616 - 5
A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline on Management of Primary Aldosteronism.
Farah MH, Hegazi M, Firwana M, et al.
The Journal of clinical endocrinology and metabolism 2025; (110(9)):e2833-e2844 doi:10.1210/clinem/dgaf290.
PMID: 40658500 - 6
SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A, Herpin D, Lefebvre H
Annales d'endocrinologie 2016; (77(3)):226-34.
PMID: 27315759 - 7
Treatment of Primary Aldosteronism.
Parisien-La Salle S, Hundemer GL, Nehs MA, et al.
Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26238 doi:10.1161/HYPERTENSIONAHA.126.26238.
PMID: 41808633 - 8
Tolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism.
Tang F, Loh LM, Foo RS, et al.
Journal of the Endocrine Society 2021; (5(11)):bvab144 doi:10.1210/jendso/bvab144.
PMID: 34541440 - 9
Efficacy and Safety of Treatment With Low Doses of Spironolactone in Patients With Primary Aldosteronism: A Retrospective Observational Study in a Tertiary Center.
Sconfienza E, Riancho J, Gebara N, et al.
Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e24881 doi:10.1161/HYPERTENSIONAHA.125.24881.
PMID: 41521906 - 10
Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M, Pelliccia F, Rosano G, et al.
International journal of cardiology 2015; (200()):25-9.
PMID: 26404748 - 11
Efficacy and safety of medical treatment of primary aldosteronism: a real-world data study in Spain.
Goi J, Paja Fano M, Rizo Gellida A, et al.
European journal of endocrinology 2025; (193(2)):297-309 doi:10.1093/ejendo/lvaf158.
PMID: 40743244 - 12
Taiwan mini-frontier of primary aldosteronism: Updating treatment and comorbidities detection.
Chan CK, Chang YY, Tsai YC, et al.
Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(10)):1811-1820 doi:10.1016/j.jfma.2021.03.032.
PMID: 33906783 - 13
Emerging Medical Therapies for Primary Aldosteronism.
Vibhatavata P, Turcu AF
Hypertension (Dallas, Tex. : 1979) 2026; (83(5)):e26229 doi:10.1161/HYPERTENSIONAHA.126.26229.
PMID: 41685462 - 14
Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
Rakugi H, Yamakawa S, Sugimoto K
Hypertension research : official journal of the Japanese Society of Hypertension 2021; (44(4)):371-385 doi:10.1038/s41440-020-00569-y.
PMID: 33214722 - 15
Renal damage in primary aldosteronism: a systematic review and meta-analysis.
Monticone S, Sconfienza E, D'Ascenzo F, et al.
Journal of hypertension 2020; (38(1)):3-12 doi:10.1097/HJH.0000000000002216.
PMID: 31385870 - 16
Associations Between Changes in Plasma Renin Activity and Aldosterone Concentrations and Changes in Kidney Function After Treatment for Primary Aldosteronism.
Kobayashi Y, Haze T, Yano Y, et al.
Kidney international reports 2020; (5(8)):1291-1297 doi:10.1016/j.ekir.2020.06.012.
PMID: 32775828 - 17
Association Between Plasma Aldosterone Concentration and Intraglomerular Hemodynamics in Primary Aldosteronism.
Uedono H, Kurajoh M, Toi N, et al.
American journal of hypertension 2024; (37(10)):801-809 doi:10.1093/ajh/hpae071.
PMID: 38776410 - 18
Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments.
Wu VC, Chan CK, Chueh JS, et al.
Journal of the American Heart Association 2023; (12(4)):e028146 doi:10.1161/JAHA.122.028146.
PMID: 36789834 - 19
Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy.
Nakano Y, Yoshimoto T, Fukuda T, et al.
Internal medicine (Tokyo, Japan) 2018; (57(17)):2459-2466 doi:10.2169/internalmedicine.0438-17.
PMID: 29709927
This comparison is for education about medicines used for primary aldosteronism and does not replace medical advice. Do not start, stop, or change either medicine without your clinician's guidance.